Capricor Therapeutics (CAPR) CFO Bergmann Sells $12K of Stock
On June 24, 2026, CFO Anthony Bergmann sold 400 shares of Capricor Therapeutics for about $12,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Anthony Bergmann, CHIEF FINANCIAL OFFICER at Capricor Therapeutics, Inc. ($CAPR), sold 400 shares at an average price of $30, worth about $12,000, on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CAPR is down 21.8% after 1 week, down 33.2% after 1 month and down 77.3% to date (from the $29.51 close on Jun 24, 2026).
CAPR
Capricor Therapeutics, Inc.
Key Points
- CFO Anthony Bergmann sold 400 shares of Capricor Therapeutics for about $12,000 on June 24, 2026.
- The stock closed at $29.51 on the day of the transaction, having seen a high of $40.37 in the past year.
- Bergmann has been active, also buying shares recently, which reflects his ongoing involvement with Capricor.
Get $CAPR trade alerts by text
We text you when insiders, Congress or big funds trade $CAPR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Capricor Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Capricor Therapeutics, Inc.
CFO Anthony Bergmann sold 400 shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) on June 24, 2026. This sale was valued at about $12,000, with the shares sold at $30 each. This transaction is part of a recent pattern of trading activity by Bergmann.
Recent Insider Transactions
Bergmann's recent trades show a mix of buying and selling shares. On June 25, 2026, he purchased 24,100 shares at around $3.18, valued at about $76,638. Earlier, on June 22, he sold 500 shares, valued at approximately $15,000. Meanwhile, Karen Krasney, EVP and General Counsel, also sold shares on the same day, showing active trading among the company's insiders.
How Capricor Therapeutics, Inc. Stock Has Traded
Capricor Therapeutics shares closed at $29.51 on June 24, 2026. This price is significantly higher than its 52-week low of $2.96, indicating a strong increase over the year. The stock's recent performance may reflect investor interest as the company continues its work in biotechnology, specifically in developing therapies for Duchenne muscular dystrophy.
What Capricor Therapeutics, Inc. Does
Capricor Therapeutics is a biotechnology company focused on developing cell and exosome-based therapies for serious health conditions. With a market cap of about $517 million, the company is working on innovative treatments, including its lead product candidate, Deramiocel, which is in phase 3 trials.
What's Ahead for Capricor Therapeutics, Inc.
Investors should keep an eye on upcoming earnings, scheduled for November 10, 2026. The recent insider transactions may provide insights into the company's internal outlook. Remember, the trades reported are based on the SEC's STOCK Act disclosures, reflecting actions taken in the past.
Related Filing Alerts
Source: Anthony Bergmann's Form 4 filing on $CAPR (Jun 24, 2026). Find the original filing: CAPR Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts